Litcius/Paper detail

Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19

Aymeric Silvin, Nicolas Chapuis, Garett Dunsmore, Anne‐Gaëlle Goubet, Agathe Dubuisson, Lisa Derosa, Carole Almire, Clémence Henon, Olivier Kosmider, Nathalie Droin, Philippe Rameau, Cyril Catelain, Alexia Alfaro, Charles Dussiau, Chloé Friedrich, Élise Sourdeau, Nathalie Marin, Tali‐Anne Szwebel, Delphine Cantin, Luc Mouthon, Didier Borderie, Marc Deloger, Delphine Bredel, Séverine Mouraud, Damien Drubay, Muriel Andrieu, Anne-Sophie L’Honneur, Véronique Saada, Annabelle Stoclin, Christophe Willekens, Fanny Pommeret, Frank Griscelli, Lai Guan Ng, Zheng Zhang, Pierre Bost, Ido Amit, Fabrice Barlési, Aurélien Marabelle, Frédéric Pène, Bertrand Gachot, Fabrice André, Laurence Zitvogel, Florent Ginhoux, Michaëla Fontenay, Éric Solary

2020Cell921 citationsDOIOpen Access PDF

Topics & Concepts

BiologyMyeloid cellsCoronavirus disease 2019 (COVID-19)CalprotectinMyeloidImmunologyVirologyCell2019-20 coronavirus outbreakCancer researchInternal medicineGeneticsDiseaseInflammatory bowel diseaseMedicineInfectious disease (medical specialty)OutbreakS100 Proteins and AnnexinsImmune Response and InflammationImmune responses and vaccinations
Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19 | Litcius